INTRODUCTION

Viruses are the simplest form of life, carrying genetic materials and the capacity to efficiently enter target host cells. Because of these properties, numerous types of viruses have been adapted as gene transfer vectors,1–3 for which purpose adenoviruses have been well studied and characterized. Adenoviruses are large, double-stranded DNA viruses exhibiting tropism for many human tissues, such as bronchial epithelia, hepatocytes, and neurons. Moreover, adenoviruses can transduce nonreplicating cells and be grown to high titers in vitro, which allows for their potential clinical use. Replication-defective adenoviruses can be produced at high titers and have been used in gene transfer and gene therapy applications. However, adenoviruses are not naturally tumorigenic, and their use has been limited by the induction of immune responses, the risk of viral persistence, and their inability to infect nondividing cells. To overcome these limitations, adenoviruses have been modified to deliver therapeutic genes selectively to cancer cells.

...
successfully used to express genes in eukaryotic cells. A variety of adeno viral gene therapy agents has been tested in various studies using in vitro and animal models. The tolerability, safety, and potential beneficial effects of these agents have been described for different target diseases, however, the three-dimensional spread of replication-deficient adenoviruses after intratumoral administration might be less than ideal.

Oncolytic viruses that can selectively replicate in tumor cells and lyse infected cells have been extensively investigated as novel anticancer agents. These vectors are designed to induce virus-mediated lysis of tumor cells after selective intracellular propagation while remaining innocuous to normal tissues. The optimal treatment of human cancers requires improvement of the therapeutic ratio to increase the cytotoxicity to tumor cells and decrease that against normal cells. This may not be an easy task, because the majority of normal cells surrounding tumors are sensitive to cytotoxic agents. Thus, to establish reliable therapeutic strategies for human cancers, it is important to seek genetic and epigenetic targets present only in cancer cells. One targeting strategy involves the use of tissue-specific promoters to restrict gene expression or virus replication to specific tissues. A large number of different tissue-specific promoters such as prostate-specific antigen (PSA), Mucin 1, osteocalcin, L-plastin, midkine, and E2F-1 have been used for virotherapy applications. However, for targeting tumors derived from various tissues, tumor-specific, rather than tissue-specific, promoters would be more advantageous. For example, the promoter for human telomerase reverse transcriptase (hTERT) is highly active in most tumor cells but inactive in normal somatic cells.

2 | TELOMERASE ACTIVITY FOR TRANSCRIPTIONAL CANCER TARGETING

One of the hallmarks of cancer is the unregulated proliferation of specific cell populations, which eventually affects normal cellular function throughout the body, and this is almost universally correlated with telomerase reactivation. Telomerase is a ribonucleoprotein complex that mediates the addition of TTAGGG repeats to the telomeric ends of chromosomes. The enzyme consists of three components: an RNA subunit (known as hTR, hTER, or hTERC), telomerase-associated protein (hTEP1), and the catalytic subunit (hTERT). Both hTR and hTERT are required for the reconstitution of telomerase activity in vitro and thus represent the minimal catalytic core of telomerase in humans. However, although hTR is widely expressed in embryonic and somatic tissues, hTERT expression is tightly regulated and not detectable in most somatic cells. The strong association between telomerase activity and malignant tissues suggests that telomerase is a plausible target for the treatment of cancer. Thus, the hTERT proximal promoter can be used as a molecular switch for the selective expression of target genes in tumor cells, as almost all advanced human cancer cells express telomerase, whereas most normal cells do not.

3 | GENETIC ENGINEERING OF AN HTERT PROMOTER-DRIVEN ONCOLYTIC ADENOVIRUS

The use of modified adenoviruses that replicate and complete their lytic cycles preferentially in cancer cells is a promising strategy for the treatment of cancer. One approach to achieve tumor specificity of viral replication is based on the transcriptional control of genes that are critical for virus replication, such as E1A and E1B. The catalytic subunit of telomerase, hTERT, is expressed in the majority of human cancers, and the hTERT promoter is preferentially activated in a variety of human cancer cells. Therefore, the hTERT promoter may be a suitable regulator of adenoviral replication. It was previously reported that transcriptional control of E1A expression by the hTERT promoter restricts adenoviral replication to telomerase-positive tumor cells, resulting in efficient lysis of the tumor cells.

We also examined the adenovirus E1B gene, which is expressed early in viral infection, and its gene product inhibits E1A-induced p53-dependent apoptosis, which in turn promotes the cytoplasmic accumulation of late viral messenger RNA (mRNA), leading to a shutdown of host cell protein synthesis. In most vectors that replicate under transcriptional control of the E1A gene, including hTERT-specific oncolytic adenoviruses, the E1B gene is driven by the endogenous adenovirus E1B promoter. However, it was previously reported that transcriptional control of both the E1A and E1B genes by a single tumor-specific promoter with the use of an internal ribosome entry site significantly improves the specificity and therapeutic index in particular human tumor cells. Thus, we developed telomelysin (OBP-301), in which the tumor-specific hTERT promoter regulates expression of both the E1A and E1B genes (Figure 1). Telomelysin is expected to control viral replication more stringently, thereby providing greater therapeutic efficacy against tumor cells, as well as attenuated toxicity in normal tissues.

4 | PRECLINICAL STUDIES OF THE HTERT PROMOTER-DRIVEN ONCOLYTIC ADENOVIRUS

In preclinical experiments, telomelysin-induced selective E1A and E1B expression in cancer cells, which resulted in virus replication at 5-6 logs by 3 days after infection, but telomelysin replication was attenuated up to 2 logs in cultured normal cells. In vitro cytotoxicity assays demonstrated that telomelysin efficiently kills both epithelial and mesenchymal types of malignant tumor cells (including those of lung cancer, gastric cancer, esophageal cancer, colorectal cancer, head and neck cancer, hepatic cancer, cervical cancer, breast cancer, osteosarcoma, pancreas cancer, prostate cancer, melanoma, and mesothelioma) in a dose-dependent manner (Figure 2). In addition, intratumoral injection of telomelysin in subcutaneous and orthotopic xenograft tumor models was efficacious in treatment of both primary tumors and regional lymph node metastasis. Indeed, when telomelysin was intratumorally injected into human colorectal tumors orthotopically implanted into the rectum in nude mice, telomelysin caused viral
spread into the regional lymphatic area and selectively replicated in neoplastic lesions, resulting in tumor cell-specific death in metastatic lymph nodes. Thus, telomelysin not only exhibits features that make it desirable for use as an oncolytic therapeutic agent, the proportion of cancers potentially treatable using telomelysin is extremely high.

To further enhance the antitumor effect of telomelysin-based oncolytic virotherapy, we evaluated the therapeutic potential of telomelysin in combination with conventional radiotherapy. Ionizing radiation primarily induces double-strand breaks (DSBs) in DNA molecules. Radiosensitization can result from a therapeutic increase in DNA DSBs or inhibition of their repair. The MRN complex, consisting of Mre11, Rad50, and NBS1, is quickly stimulated by DSBs and directly activates ataxia-telangiectasia mutated (ATM), an important signal transducer in the DNA damage repair response, which involves DNA repair and cell cycle checkpoints. Therefore, defects in the MRN complex induce hypersensitivity to DNA damage. We found that expression of the MRN complex in cancer cells decreased after telomelysin infection when E1B 55-kDa protein expression began, leading to inhibition of ATM phosphorylation by ionizing radiation and inhibition of DNA repair (Figure 3). Telomelysin infection apparently sustains elevated levels of γH2AX (a hallmark of DNA DSBs) for longer periods in irradiated tumor cells. These findings indicate that tumor cells infected with telomelysin could be rendered sensitive to ionizing radiation.

5 | CLINICAL APPLICATION OF THE HTERT PROMOTER-DRIVEN ONCOLYTIC ADENOVIRUS AS MONOTHERAPY

Many clinical trials of adenoviruses testing their oncolytic properties are well underway (Table 1). To explore the clinical application of telomelysin, Oncolys BioPharma Inc. was established in March 2004 as an Okayama University-launched bio-venture company. Based on preclinical studies, an open-label, phase 1 dose-escalation study of intratumoral injection of telomelysin was initiated in the USA to validate the safety, tolerability, and feasibility of telomelysin as monotherapy in patients with advanced solid tumors. The trial commenced following approval by the US Food and Drug Administration in October 2006. The doses of telomelysin were escalated in 1-log increments from low to high virus particles (vp). Sixteen patients with a variety of solid tumors, such as melanoma, head and neck cancer, breast cancer, lung cancer, and sarcomas,
were treated with a single-dose intratumoral injection of telomelysin and then monitored over 1 month.

All patients received telomelysin without dose-limiting toxicity. Common grade 1 and 2 toxicities included injection site reactions (pain, induration) and systemic reactions (fever, chills). Pharmacokinetic and biodistribution data for telomelysin were of particular interest. Circulating viral DNA was transiently (<6 h after injection) detected in plasma from 13 of 16 patients within 24 h after injection. This dose-dependent initial peak in circulating virus titer was followed by a rapid decline; however, three patients demonstrated evidence of prolonged viral replication through detection of viral DNA in plasma on days 7 and 14, suggesting the replication of telomelysin in primary tumors. In one of these patients, the injected malignant lesion and loco-regional un.injected satellite nodules disappeared, fulfilling the definition of a complete response (CR) at day 28. Eleven patients satisfied RECIST criteria for stable disease response in the injected lesion at day 28, whereas three patients had progressive disease, and two patients were unevaluable. Six patients exhibited reductions in tumor size of 6.6%-33%, and one of these patients exhibited a 33% reduction in the size of the injected lesion at day 28 and 56.7% reduction at day 56. These clinical data suggest that telomelysin is well-tolerated and warrants further clinical studies of its use in treating solid cancers.

FIGURE 2  Oncolytic effects of telomelysin in vitro on a variety of human cancer cell lines. Cells were infected with telomelysin at indicated multiplicity of infections (MOI) values, and surviving cells were quantitated over 5 days by XTT assay. Data are mean ±SD

6 | MULTIDISCIPLINARY APPROACH USING THE HTERT PROMOTER-DRIVEN ONCOLYTIC ADENOVIRUS

The advantage of combination therapy with telomelysin plus conventional radiotherapy is that the areas in which each treatment demonstrates its
therapeutic effect overlap. We previously demonstrated that intratumorally injected telomelysin expressing the GFP gene effectively traffics to the regional lymph nodes, as viral replication produced green fluorescent protein-associated fluorescence signals in metastatic lymph nodes in orthotopic human colorectal and oral cancer xenograft models. Therefore, we hypothesize that intratumoral administration of telomelysin would radiosensitize both primary tumors and regional lymph nodes.

An open-label, phase 1, dose-escalation study was conducted in esophageal cancer patients to further determine the feasibility, efficacy, and pharmacokinetics of telomelysin in combination with radiotherapy (UMIN 000010158; Figure 4). Thirteen patients with histologically confirmed esophageal cancer who were deemed unfit to receive standard therapies such as surgery and chemotherapy were enrolled into this study. Virus administration was performed by intratumoral injection of the primary or metastatic tumor via a flexible endoscope. Study treatment consisted of intratumoral needle injections of telomelysin on days 1, 18, and 32 of treatment. Radiation therapy was administered concurrently over 6 weeks, beginning on day 4, to a total of up to 60 Gy. Virus distribution and shedding into the body fluids, including the saliva, sputum, urine, and plasma, were monitored using a quantitative DNA-polymerase chain reaction assay.

Of 13 patients, seven, three, and three patients were included in cohorts treated with $10^{10}$, $10^{11}$, and $10^{12}$ vp of telomelysin, respectively. The patient group comprised 10 men and three women, with a median age of 79.7 years (range, 53-92 years). Common grades 1 and 2 toxicities included fever, esophagitis, pneumonitis, anorexia, constipation, and gastroesophageal reflux. All patients developed a transient, self-limited lymphopenia. Distribution studies revealed the presence of viral DNA in five of the six patients who received $10^{11}$ or $10^{12}$ vp of telomelysin, but this was rarely detected in the gargle, saliva, and urine. Eight patients had a local CR; all of these patients exhibited no viable malignant cells in biopsy specimens. Three patients had a partial response. The objective response rate was 91.7%. The clinical CR rate was 83.3% in stage I and 60.0% in stages II and III. Histopathologic examination of post-treatment specimens showed massive infiltration of CD8$^+$ cells in three partial response tumors. These findings indicate that treatment involving multiple

**FIGURE 3** Molecular mechanism of telomelysin-induced radiosensitization. The MRN complex plays a role as an upstream sensor in response to DNA double-strand breaks. Degradation of the MRN complex by E1B 55-kDa protein prevents ataxia-telangiectasia mutated (ATM) autophosphorylation and signaling, leading to inhibition of the ATM-dependent G2/M checkpoint.
### TABLE 1 Oncolytic adenoviruses in clinical testing

| Oncolytic adenovirus | Serotype | Mechanism of action | Indication(s)       | Clinical phase | Ref. |
|---------------------|----------|---------------------|---------------------|----------------|------|
| CG0070              | Adenovirus type 5 | Human E2F-1 promoter drives E1A gene | Bladder            | Phases I/II | 40   |
|                     |          | Armed by the addition of the GM-CSF gene |                     |                |      |
| DNX-2401/AdΔ24-RGD (tasadenoturev) | Adenovirus type 5 | E1A-Δ24 mutation in pRb-binding site | Brain              | Phases I & II | 41  |
|                     |          | Integrin-binding RGD motif |                     |                |      |
| ColoAd1 (enadenotucirev) | Adenovirus type 3/11p | Group B Ad11p/Ad3 chimeric adenovirus | Solid tumors       | Phases I & I/II | 42  |
| ONCOS-102           | Adenovirus type 5/3 | E1A-Δ24 mutation in pRb-binding site | Solid tumors       | Phases I & I/II | 43  |
|                     |          | Pseudotyped with Ad3 knob |                     |                |      |
|                     |          | Armed by the addition of the GM-CSF gene |                     |                |      |
| VCN-01              | Adenovirus type 5 | E1a mutated in the pRb-binding site | Pancreatic cancer  | Phase I     | 44  |
|                     |          | Retargeting RGDK modification of the fiber |                     |                |      |
|                     |          | Expression of hyaluronidase |                     |                |      |
| OBP-301 (telomelysin) | Adenovirus type 5 | Human telomerase reverse transcriptase promoter drives E1 genes | Esophageal cancer | Phases I/II & II | 45  |
|                     |          | HCC, melanoma |                     |                |      |

**A**

**Patient with esophageal cancer**
- Age ≥ 20 y
- Histologically confirmed esophageal cancer for whom standard therapies were not available due to the old age or prevalence of frailty
- Lesions accessible for repeated injection measurable disease
- Tumor area of <25 cm² and >1 cm²
- ECOG performance status 0-2
- Adequate bone marrow, liver, and renal function

**Primary endpoint:** safety (incidence of dose-limiting toxicities)
**Secondary endpoints:** objective response rate (ORR), progression-free survival (PFS), overall survival (OS)

---

**B**

**Oncolytic virotherapy OBP-301 (telomelysin)**
- **Dose:**
  - Level 1: $1 \times 10^{10}$ virus particles (vp)
  - Level 2: $1 \times 10^{11}$ vp
  - Level 3: $1 \times 10^{12}$ vp
- **Endoscopic injection on day 1, 18, and 32**

**Radiotherapy**
- Total 60 Gy (5 times/wk × 6 wk)

---

**FIGURE 4** Schematic outline of strategies for treating esophageal cancer. A. Synopsis of the study design and objectives. B. Schematic illustration of the treatment schedule. Patients with esophageal cancer who are not eligible for standard treatments receive intratumoral needle injections of telomelysin on days 1, 18, and 32. Radiation therapy is administered concurrently over 6 weeks, beginning on day 4, up to a total of 60 Gy.
courses of endoscopic telomelysin injection in combination with radiotherapy is feasible and provides clinical benefits in patients with esophageal cancer, particularly those who are unfit for standard treatments.

7 | NEXT-GENERATION MULTIFUNCTIONAL HTERT PROMOTER-DRIVEN ONCOLYTIC ADENOVIRUS

Oncolytic viruses armed to express several types of therapeutic transgenes have been reported. Among candidate therapeutic transgenes, the tumor suppressor p53 gene is particularly potent and exhibits a variety of effects, including induction of cell cycle arrest, apoptosis, senescence, and DNA repair. Indeed, a p53-expressing replication-deficient adenovirus (Ad-p53, Advexin) was shown to induce antitumor effects both in vitro and in vivo, as well as in various clinical studies. Therefore, to develop a next-generation HTERT promoter-driven oncolytic adenovirus, we modified telomelysin (OBP-301) to express the wild-type p53 tumor suppressor gene (OBP-702; Figure 1) and compared the antitumor activity of OBP-702 with that of telomelysin.

The antitumor effects of OBP-702 and telomelysin were compared using telomelysin-sensitive and -resistant human cancer cells. OBP-702 suppressed the viability of both telomelysin-sensitive and -resistant cancer cells more efficiently than telomelysin. OBP-702 exhibited greater induction of apoptosis of cancer cells compared to telomelysin and replication-deficient Ad-p53. Adenovirus E1A-mediated miR-93/106b upregulation induced p21 suppression followed by MDM2 downregulation, leading to p53-mediated apoptosis in OBP-702-infected cells. p53 overexpression enhanced adenovirus-mediated autophagy via activation of the damage-regulated autophagy modulator (DRAM). Moreover, OBP-702 significantly suppressed tumor growth in subcutaneous and orthotopic tumor xenograft models compared to monotherapy with telomelysin or Ad-p53. These findings suggest that OBP-702-mediated p53 trans-activation is a promising antitumor strategy for inducing both apoptotic and autophagic cell death pathways via regulation of microRNA and DRAM in human cancers.

To produce high-titer virus in quantities required for clinical trials, large-scale manufacturing of OBP-702 is ongoing under Good Manufacturing Practice conditions.

8 | CONCLUSIONS AND PERSPECTIVES

Significant advances have been made in our understanding of the molecular aspects of human gastrointestinal cancers and the development of technologies for viral genome modification. Transcriptional targeting is a powerful tool that enables tumor selectivity in cancer therapy, and the HTERT promoter-driven oncolytic adenovirus we developed exhibits more specific targeting potential due to the amplifying effects of viral replication.

A promising future application for telomelysin includes combination therapy with conventional approaches such as radiotherapy, chemotherapy, surgery, and immunotherapy. Indeed, in April 2019, the Japanese Ministry of Health, Labour and Welfare designated telomelysin in combination with radiotherapy an innovative pharmaceutical product under the SAKIGAKE Designation System. Designated products are eligible for prioritized consultation services, with a reduction in the premarket review period to as short as 6 months, half the standard review period of 12 months. Moreover, Oncolys BioPharma Inc. granted an exclusive license to Chugai Pharmaceutical Co., Ltd., one of Japan’s leading research-based pharmaceutical companies, concerning the development, manufacture, and marketing of telomelysin in Japan and Taiwan. It is expected these events will accelerate the clinical development of telomelysin.

Clinical trials of telomelysin in combination with immunotherapy or chemoradiotherapy are also underway. An open-label, phase 1 study (EPOC1505) has been conducted to evaluate the safety and efficacy of telomelysin with anti-programmed death 1 (PD-1) antibody, pembrolizumab, in patients with advanced solid tumors. A phase 2 study of telomelysin in combination with pembrolizumab for esophageal adenocarcinoma was initiated in May 2019 at Weill Cornell Medical College in the USA. Moreover, NRG Oncology, a non-profit research organization in the USA, is planning a phase 1 study of telomelysin combined with definitive chemoradiation consisting of carboplatin/paclitaxel for treating locally advanced esophageal cancer in patients who are medically inoperable.

The field of targeted oncolytic virotherapy has progressed considerably, such that it is rapidly gaining medical and scientific acceptance. Although some conceptual and regulatory problems remain to be solved, ongoing and future clinical studies are expected to provide important data that will lead to further substantial progress in human gastrointestinal cancer therapies.

DISCLOSURE

Funding: This study was supported by grants-in-aid from the Ministry of Education Culture, Sports, Science and Technology, Japan (to T. Fujiwara; No. 16673992), grants from the Ministry of Health, Labor and Welfare, Japan (to T. Fujiwara; No. 11949927, No. 13801458, No. 14525167), and grants from the Japan Agency for Medical Research and Development (to T. Fujiwara; No. 15652856). The majority of this review was presented at the 2016 JSGS Science of the Year award ceremony.

Conflict of interest: Toshiyoshi Fujiwara is a medical advisor for Oncolys BioPharma Inc. and received research grants from Oncolys BioPharma Inc.

Author Contribution: TF is solely responsible for the literature review and drafting of the manuscript.

ORCID

Toshiyoshi Fujiwara https://orcid.org/0000-0002-5377-6051
REFERENCES

1. Kaplan JM. Adenovirus-based cancer gene therapy. Curr Gene Ther. 2005;5:595–605.

2. Guo ZS, Thorne SH, Bartlett DL. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta. 2008;1785:217–31.

3. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer. 2009;9:64–71.

4. Waku T, Fujiwara T, Shao J, Itoshima T, Murakami T, Kataoka M, et al. Contribution of CD95 ligand-induced neutrophil infiltration to the bystander effect in p53 gene therapy for human cancer. J Immunol. 2000;165:5884–90.

5. Tsunemitsu Y, Kagawa S, Tokunaga N, Otani S, Umeoka T, Roth JA, et al. Molecular therapy for peritoneal dissemination of xenotransplanted human MKN-45 gastric cancer cells with adenovirus mediated Bax gene transfer. Gut. 2004;53:554–60.

6. Clayman GL, el-Naggar AK, Lippman SM, Henderson YC, Frederick SD, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 1997;90:785–95.

7. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science. 1997;277:955–9.

8. Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, et al. Telomerase activation by hTERT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet. 1998;18:65–8.

9. Beattie TL, Zhou W, Robinson MO, Harrington L. Reconstitution of human telomerase activity in vitro. Curr Biol. 1999;8:177–80.

10. Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell. 2002;2:257–65.

11. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, et al. A conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther. 2003;14:1415–28.

12. Lanson NA Jr, Friedlander PL, Schwarzenberger P, Kolls JK, Wang G. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. Cancer Res. 2003;63:7936–41.

13. Wirth T, Zender L, Schulte B, Mundt B, Plentz R, Rudolph KL, et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res. 2003;63:3181–8.

14. Irving J, Wang Z, Powell S, O’Sullivan C, Mok M, Murphy B, et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther. 2004;11:174–85.

15. Li Y, Yu DC, Chen Y, Zhang H, Nguyen N, et al. A hepatocellular carcinoma-specific adenovirus variant, CV990, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res. 2001;61:6428–36.

16. Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F, et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res. 2004;10:285–92.

17. Hashimoto Y, Watanabe Y, Shirakiya Y, Uno F, Kagawa S, Kawamura H, et al. Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus. Cancer Sci. 2008;99:385–90.

18. Sasaki T, Tazawa H, Hasei J, Kunisada T, Yoshida A, Hashimoto Y, et al. Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas. Clin Cancer Res. 2011;17:1828–38.

19. Kojima T, Watanabe Y, Hashimoto Y, Kuroda S, Yamasaki Y, Yano S, et al. In vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy. Ann Surg. 2010;251:1079–86.

20. Kikuchi S, Kishimoto H, Tazawa H, Hashimoto Y, Kuroda S, Nishizaki M, et al. Biological ablation of sentinel lymph node metastasis in submucosally invaded early gastrointestinal cancer. Mol Ther. 2015;23:501–9.

21. D’Amours D, Jackson SP. The Mre11 complex: at the crossroads of DNA repair and checkpoint signalling. Nat Rev Mol Cell Biol. 2002;3:317–27.

22. Theunissen JW, Kaplan MI, Hunt PA, Williams BR, Ferguson DO, Alt FW, et al. Checkpoint failure and chromosomal instability without lymphomagenesis in Mre11(Atld1/Atld1) mice. Mol Cell. 2003;12:1511–23.
39. Kuroda S, Fujiwara T, Shirakawa Y, Yamasaki Y, Yano S, Uno F, et al. Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery. Cancer Res. 2010;70:9339–48.

40. Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL 3rd, et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results. Urol Oncol. 2018;36:440–7.

41. Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018;36:1419–27.

42. Garcia-Carbonero R, Salazar R, Duran I, Osman-Garcia I, Paz-Ares L, Bozada JM, et al. Phase I study of intravenous administration of the chimeric adenovirus ONCOS-102 in patients undergoing primary tumor resection. J Immunother Cancer. 2017;5:71.

43. Ranki T, Pesonen S, Hemminki A, Partanen K, Kairemo K, Alanko T, et al. Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. J Immunother Cancer. 2016;4:17.

44. Rodríguez-García A, Giménez-Alejandre M, Rojas JJ, Moreno R, Bazan-Peregrino M, Cassánd M, et al. Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGDL and hyaluronidase expression. Clin Cancer Res. 2015;21:1406–18.

45. Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C, et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelynis) for various solid tumors. Mol Ther. 2010;18:429–34.

46. Kishimoto H, Kojima T, Watanabe Y, Kagawa S, Fujiwara T, Uno F, et al. In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat Med. 2006;12:1213–9.

47. Kurihara Y, Watanabe Y, Onimatsu H, Kojima T, Shirota T, Hatori M, et al. Telomerase-specific virotheranostics for human head and neck cancer. Clin Cancer Res. 2009;15:2335–43.

48. Breitbach CJ, Thorne SH, Bell JC, Kirn DH. Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594. Curr Pharm Biotechnol. 2012;13:1768–72.

49. Cerullo V, Capasso C, Vaha-Koskela M, Hemminki O, Hemminki A. Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System. Curr Cancer Drug Targets. 2018;18:124–38.

50. Laptenko O, Prives C. p53: master of life, death, and the epigenome. Genes Dev. 2017;31:955–6.

51. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst. 1994;86:1458–62.

52. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 1994;54:2287–91.

53. Ma G, Kawamura K, Li Q, Suzuki N, Liang M, Namba M, et al. Cytotoxicity of adenoviruses expressing the wild-type p53 gene to esophageal carcinoma cells is linked with the CAR expression level and indirectly with the endogenous p53 status. Cancer Gene Ther. 2009;16:832–40.

54. Fujiwara T, Tanaka N, Kanazawa S, Ohtani S, Saijo Y, Nukiwa T, et al. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2006;24:1689–99.

55. Shimada H, Matsubara H, Shiratori T, Shimizu T, Miyazaki S, Okazumi S, et al. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sci. 2006;97:554–61.

56. Yamasaki Y, Tazawa H, Hashimoto Y, Kojima T, Kuroda S, Yano S, et al. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression. Eur J Cancer. 2012;48:2282–91.

57. Hasemi S, Sasaki T, Tazawa H, Osaki S, Yamakawa Y, Kunisada T, et al. Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells. Mol Cancer Ther. 2013;12:314–25.

How to cite this article: Fujiwara T. Multidisciplinary oncolytic virotherapy for gastrointestinal cancer. Ann Gastroenterol Surg. 2019;3:396–404. https://doi.org/10.1002/ags3.12270